Levomepromazine for schizophrenia

Abstract

Levomepromazine is an ‘older’ typical antipsychotic licensed for use in schizophrenia but sparingly prescribed in the UK. Our objective is to determine the clinical effects and safety of levomepromazine compared with placebo or antipsychotics for schizophrenia and schizophreniform psychoses. All randomised trials comparing levomepromazine with placebo or other antipsychotics for schizophrenia and schizophreniform psychoses were included in our systematic review which currently includes 4 RCTs with 192 participants. For our primary outcome of leaving the study early, levomepromazine was not significantly different compared with other antipsychotics. The levomepromazine arm was significantly b..